MLchartDataset catalogue

autologous CD19-28z chimeric antigen receptor-expressing T lymphocytes

Term · Oncology and biomedicine · MLC-T-ONC-011538

Genetically modified autologous T-lymphocytes transduced with a replication-incompetent retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, autologous CD19-28z CAR-expressing T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.

Table 1. Record
IdentifierMLC-T-ONC-011538
FieldOncology and biomedicine
SynonymsCAR 19-28z T cells
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011538",
  "term": "autologous CD19-28z chimeric antigen receptor-expressing T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "Genetically modified autologous T-lymphocytes transduced with a replication-incompetent retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, autologous CD19-28z CAR-expressing T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.",
  "synonyms": [
    "CAR 19-28z T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-cd19-28z-chimeric-antigen-receptor-expressing-t-lymphocytes/"
}

Record 2,872 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.